Lenalidomidă Stada (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, causing selective degradation of transcription factors Ikaros and Aiolos. This modulates cytokine release, enhances T‑cell and NK‑cell immune responses, and inhibits angiogenesis, together producing anti‑cancer activity in plasma‑cell disorders.

The specific dose and schedule of Lenalidomidă Stada are determined by the treating physician based on the patient’s diagnosis, disease stage, renal function, and concomitant therapies. Prescribers follow approved labeling and clinical guidelines to individualise therapy.

Lenalidomidă Stada is classified as pregnancy Category X, meaning it is contraindicated in pregnancy because of a high risk of fetal harm. Women of child‑bearing potential must use effective contraception, and breastfeeding is not recommended while receiving the drug.

To order Lenalidomidă Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternatives to lenalidomide are thalidomide and pomalidomide, which belong to the same immunomodulatory imide drug (IMiD) class. Lenalidomide generally offers a more favorable safety profile than thalidomide, with lower rates of peripheral neuropathy, while providing comparable anti‑myeloma efficacy. Pomalidomide is often reserved for patients who have progressed after lenalidomide therapy.

Lenalidomidă Stada tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister or bottle, protected from moisture, light and excessive heat. Keep the container tightly closed and out of reach of children.

Lenalidomidă Stada is administered orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

The most serious risks include thromboembolic events (deep‑vein thrombosis, pulmonary embolism), severe neutropenia or infections, and the development of secondary primary malignancies such as acute leukemias. Patients should be monitored closely for signs of clotting, fever, or unexplained bleeding.

Lenalidomidă Stada should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or any excipients, and patients with uncontrolled severe renal impairment unless dose adjustments are made. Caution is also advised for patients with a history of thromboembolic disease.